The goal of the Mayo Clinic Cancer Center SPORE in Brain Cancer Developmental Research Program is to support innovative and scientifically sound projects that investigate a question pertaining to some aspect of translational research in gliomas and other primary brain tumors. The premise of this program is that support of developmental research projects will result in the generation of new hypotheses that will be tested within the full SPORE-sponsored projects or through peer-reviewed external grants support. The long-term goal of the SPORE program is to translate the findings generated by developmental grants into effective interventions in patients with, and persons at risk for, primary brain tumors. More specifically, the objectives of the Developmental Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and clinical studies; (2) foster extensive collaboration between basic science, population science and clinical disciplines in brain tumor translational research; (3) encourage investigators in related fields to evaluate the potential of applying their research findings to translational research in brain tumors; and (4) generate new hypotheses to test in large-scale research projects or clinical trials that will lead to a significant reduction in the burden of disease in brain tumor patients. The Program will be administered through the Administrative Core of the SPORE. One-page outlines of two potential research projects from investigators at Mayo Clinic Rochester and Mayo Clinic Scottsdale are included to demonstrate the depth and breadth of ongoing research that can be eligible for funding through the SPORE Developmental Research Program. These two potential projects represent under-represented areas within glioma research and, if successful, would clearly impact the nation's Neuro-Oncology agenda.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA108961-01
Application #
6844513
Study Section
Special Emphasis Panel (ZCA1-GRB-V (M1))
Project Start
2004-10-01
Project End
2009-02-28
Budget Start
2004-10-01
Budget End
2005-08-31
Support Year
1
Fiscal Year
2004
Total Cost
$63,500
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Chen, Xiaoyue; Zhang, Minjie; Gan, Haiyun et al. (2018) A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun 9:2949
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Chen, Jee-Wei E; Pedron, Sara; Shyu, Peter et al. (2018) Influence of Hyaluronic Acid Transitions in Tumor Microenvironment on Glioblastoma Malignancy and Invasive Behavior. Front Mater 5:
Youland, Ryan S; Pafundi, Deanna H; Brinkmann, Debra H et al. (2018) Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas. J Neurooncol 137:583-591
Stathias, Vasileios; Jermakowicz, Anna M; Maloof, Marie E et al. (2018) Drug and disease signature integration identifies synergistic combinations in glioblastoma. Nat Commun 9:5315
Huff, Amanda L; Wongthida, Phonphimon; Kottke, Timothy et al. (2018) APOBEC3 Mediates Resistance to Oncolytic Viral Therapy. Mol Ther Oncolytics 11:1-13
Kim, Minjee; Ma, Daniel J; Calligaris, David et al. (2018) Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier. Mol Cancer Ther 17:1893-1901
Jung, Mi-Yeon; Kang, Jeong-Han; Hernandez, Danielle M et al. (2018) Fatty acid synthase is required for profibrotic TGF-? signaling. FASEB J 32:3803-3815
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2018) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets 18:177-187
Zhou, Dan; Alver, Bonnie M; Li, Shuang et al. (2018) Distinctive epigenomes characterize glioma stem cells and their response to differentiation cues. Genome Biol 19:43

Showing the most recent 10 out of 254 publications